Nature Medicine, Published online: 06 October 2026; doi:10.1038/s41591-026-04704-z
Extended follow-up of four patients with multiple myeloma treated with in vivo BCMA CAR-T cells showed limited duration of response in three patients, while one patient had sustained response to 15 months.
